Main variables	No. of employees	Total
No. of companies carrying out R&D in Biotechnology	Fewer than 250 employees	1.226
No. of companies carrying out R&D in Biotechnology	250 or more employees	122
No. of companies carrying out R&D in Biotechnology	Total 2021	1.348
%Companies according to biotechnology used: Genetic code	Fewer than 250 employees	30,5
%Companies according to biotechnology used: Genetic code	250 or more employees	36
%Companies according to biotechnology used: Genetic code	Total 2021	31
%Companies according to biotechnology used: Functional units	Fewer than 250 employees	37,6
%Companies according to biotechnology used: Functional units	250 or more employees	46,7
%Companies according to biotechnology used: Functional units	Total 2021	38,4
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Fewer than 250 employees	20,5
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	250 or more employees	33,6
%Companies according to biotechnology used: Cellular and tissue culturing and engineering	Total 2021	21,7
%Companies according to biotechnology used: Bioprocesses	Fewer than 250 employees	48,6
%Companies according to biotechnology used: Bioprocesses	250 or more employees	68,1
%Companies according to biotechnology used: Bioprocesses	Total 2021	50,3
%Companies according to biotechnology used: Sub-cellular organisms	Fewer than 250 employees	7,2
%Companies according to biotechnology used: Sub-cellular organisms	250 or more employees	18
%Companies according to biotechnology used: Sub-cellular organisms	Total 2021	8,2
%Companies according to biotechnology used: Bio-computing	Fewer than 250 employees	24
%Companies according to biotechnology used: Bio-computing	250 or more employees	25,4
%Companies according to biotechnology used: Bio-computing	Total 2021	24,1
%Companies according to biotechnology used: Nanobiotechnology	Fewer than 250 employees	11,8
%Companies according to biotechnology used: Nanobiotechnology	250 or more employees	11,5
%Companies according to biotechnology used: Nanobiotechnology	Total 2021	11,8
%Companies according to biotechnology used: Other	Fewer than 250 employees	17
%Companies according to biotechnology used: Other	250 or more employees	10,7
%Companies according to biotechnology used: Other	Total 2021	16,4
Companies in which biotechnology activities are: Main and/or exclusive	Fewer than 250 employees	639
Companies in which biotechnology activities are: Main and/or exclusive	250 or more employees	22
Companies in which biotechnology activities are: Main and/or exclusive	Total 2021	661
Companies in which biotechnology activities are: A secondary line of business	Fewer than 250 employees	166
Companies in which biotechnology activities are: A secondary line of business	250 or more employees	22
Companies in which biotechnology activities are: A secondary line of business	Total 2021	188
Companies in which biotechnology activities are: A tool necessary for production	Fewer than 250 employees	421
Companies in which biotechnology activities are: A tool necessary for production	250 or more employees	78
Companies in which biotechnology activities are: A tool necessary for production	Total 2021	500
%Company by field(s) of ultimate application of biotechnology use: Human Health	Fewer than 250 employees	45,8
%Company by field(s) of ultimate application of biotechnology use: Human Health	250 or more employees	45,9
%Company by field(s) of ultimate application of biotechnology use: Human Health	Total 2021	45,8
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Fewer than 250 employees	15,6
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	250 or more employees	11,5
%Company by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture	Total 2021	15,3
%Company by field(s) of ultimate application of biotechnology use: Food products	Fewer than 250 employees	31,5
%Company by field(s) of ultimate application of biotechnology use: Food products	250 or more employees	32
%Company by field(s) of ultimate application of biotechnology use: Food products	Total 2021	31,5
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Fewer than 250 employees	24,1
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	250 or more employees	19,6
%Company by field(s) of ultimate application of biotechnology use: Agriculture and forest production	Total 2021	23,7
%Company by field(s) of ultimate application of biotechnology use: Environment	Fewer than 250 employees	16
%Company by field(s) of ultimate application of biotechnology use: Environment	250 or more employees	11,5
%Company by field(s) of ultimate application of biotechnology use: Environment	Total 2021	15,5
%Company by field(s) of ultimate application of biotechnology use: Industry	Fewer than 250 employees	13,4
%Company by field(s) of ultimate application of biotechnology use: Industry	250 or more employees	13,1
%Company by field(s) of ultimate application of biotechnology use: Industry	Total 2021	13,4
Personnel in R&D in biotechnology (no. of persons)	Fewer than 250 employees	10.473
Personnel in R&D in biotechnology (no. of persons)	250 or more employees	5.271
Personnel in R&D in biotechnology (no. of persons)	Total 2021	15.744
Personnel in R&D in biotechnology (no. of persons): Research personnel	Fewer than 250 employees	5.914
Personnel in R&D in biotechnology (no. of persons): Research personnel	250 or more employees	2.465
Personnel in R&D in biotechnology (no. of persons): Research personnel	Total 2021	8.380
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	Fewer than 250 employees	4.558
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	250 or more employees	2.806
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel	Total 2021	7.364
Personnel in R&D in biotechnology (no. of persons). Women	Fewer than 250 employees	5.482
Personnel in R&D in biotechnology (no. of persons). Women	250 or more employees	3.242
Personnel in R&D in biotechnology (no. of persons). Women	Total 2021	8.725
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	Fewer than 250 employees	3.094
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	250 or more employees	1.426
Personnel in R&D in biotechnology (no. of persons). Women: Research personnel	Total 2021	4.521
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	Fewer than 250 employees	2.388
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	250 or more employees	1.816
Personnel in R&D in biotechnology (no. of persons). Women: Technical and auxiliary personnel	Total 2021	4.204
Personnel in R&D in biotechnology (FTE)	Fewer than 250 employees	7.354,4
Personnel in R&D in biotechnology (FTE)	250 or more employees	4.168,8
Personnel in R&D in biotechnology (FTE)	Total 2021	11.523,2
Personnel in R&D in biotechnology (FTE): Research personnel	Fewer than 250 employees	4.402,9
Personnel in R&D in biotechnology (FTE): Research personnel	250 or more employees	1.938,6
Personnel in R&D in biotechnology (FTE): Research personnel	Total 2021	6.341,6
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	Fewer than 250 employees	2.951,5
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	250 or more employees	2.230,1
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel	Total 2021	5.181,6
Personnel in R&D in biotechnology (FTE). Women	Fewer than 250 employees	3.909,3
Personnel in R&D in biotechnology (FTE). Women	250 or more employees	2.643,4
Personnel in R&D in biotechnology (FTE). Women	Total 2021	6.552,7
Personnel in R&D in biotechnology (FTE). Women: Research personnel	Fewer than 250 employees	2.305,8
Personnel in R&D in biotechnology (FTE). Women: Research personnel	250 or more employees	1.158,6
Personnel in R&D in biotechnology (FTE). Women: Research personnel	Total 2021	3.464,4
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	Fewer than 250 employees	1.603,5
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	250 or more employees	1.484,8
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel	Total 2021	3.088,3
Internal expenditure on R&D (thousands of euros)	Fewer than 250 employees	648.976
Internal expenditure on R&D (thousands of euros)	250 or more employees	388.911
Internal expenditure on R&D (thousands of euros)	Total 2021	1.037.887
1) By nature of the expense: Current expenses	Fewer than 250 employees	577.758
1) By nature of the expense: Current expenses	250 or more employees	361.713
1) By nature of the expense: Current expenses	Total 2021	939.471
1.1) Remuneration to research personnel	Fewer than 250 employees	213.250
1.1) Remuneration to research personnel	250 or more employees	108.275
1.1) Remuneration to research personnel	Total 2021	321.525
1.2) Remuneration to technical and auxiliary personnel	Fewer than 250 employees	104.359
1.2) Remuneration to technical and auxiliary personnel	250 or more employees	90.297
1.2) Remuneration to technical and auxiliary personnel	Total 2021	194.656
1.3) Other current expenses	Fewer than 250 employees	260.148
1.3) Other current expenses	250 or more employees	163.141
1.3) Other current expenses	Total 2021	423.290
2) By nature of the expense: Capital expenses	Fewer than 250 employees	71.218
2) By nature of the expense: Capital expenses	250 or more employees	27.197
2) By nature of the expense: Capital expenses	Total 2021	98.416
2.1) Land and buildings	Fewer than 250 employees	8.904
2.1) Land and buildings	250 or more employees	1.246
2.1) Land and buildings	Total 2021	10.150
2.2) Equipment and instruments	Fewer than 250 employees	48.703
2.2) Equipment and instruments	250 or more employees	23.835
2.2) Equipment and instruments	Total 2021	72.538
2.3) Acquisition of specific R&D software	Fewer than 250 employees	3.749
2.3) Acquisition of specific R&D software	250 or more employees	1.963
2.3) Acquisition of specific R&D software	Total 2021	5.713
2.4) Otros productos de propiedad intelectual específicos para I+D	Fewer than 250 employees	9.862
2.4) Otros productos de propiedad intelectual específicos para I+D	250 or more employees	153
2.4) Otros productos de propiedad intelectual específicos para I+D	Total 2021	10.015
1.1) By origin of the funds: Own funds	Fewer than 250 employees	428.118
1.1) By origin of the funds: Own funds	250 or more employees	282.919
1.1) By origin of the funds: Own funds	Total 2021	711.037
1.2) By origin of the funds: From companies	Fewer than 250 employees	87.264
1.2) By origin of the funds: From companies	250 or more employees	34.331
1.2) By origin of the funds: From companies	Total 2021	121.595
1.3) By origin of the funds: Public Administration funds	Fewer than 250 employees	81.113
1.3) By origin of the funds: Public Administration funds	250 or more employees	26.309
1.3) By origin of the funds: Public Administration funds	Total 2021	107.422
1.4) By origin of the funds: From Universities	Fewer than 250 employees	192
1.4) By origin of the funds: From Universities	250 or more employees	0
1.4) By origin of the funds: From Universities	Total 2021	192
1.5) By origin of the funds: From non profit private institutions	Fewer than 250 employees	1.543
1.5) By origin of the funds: From non profit private institutions	250 or more employees	9.213
1.5) By origin of the funds: From non profit private institutions	Total 2021	10.756
1.6) By origin of the funds: Foreign funds	Fewer than 250 employees	50.745
1.6) By origin of the funds: Foreign funds	250 or more employees	36.139
1.6) By origin of the funds: Foreign funds	Total 2021	86.884
Purchase of R&D services in biotechnology (thousands of euros)	Fewer than 250 employees	77.001
Purchase of R&D services in biotechnology (thousands of euros)	250 or more employees	68.440
Purchase of R&D services in biotechnology (thousands of euros)	Total 2021	145.440
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Fewer than 250 employees	54.755
Purchase of R&D services in biotechnology (thousands of euros): In Spain	250 or more employees	41.115
Purchase of R&D services in biotechnology (thousands of euros): In Spain	Total 2021	95.870
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Fewer than 250 employees	22.246
Purchase of R&D services in biotechnology (thousands of euros): Abroad	250 or more employees	27.324
Purchase of R&D services in biotechnology (thousands of euros): Abroad	Total 2021	49.570
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Fewer than 250 employees	41,6
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	250 or more employees	21,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital	Total 2021	39,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Fewer than 250 employees	12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	250 or more employees	12,3
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information	Total 2021	12,5
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Fewer than 250 employees	18,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	250 or more employees	14,8
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources	Total 2021	18,5
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Fewer than 250 employees	10,9
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	250 or more employees	14,8
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain	Total 2021	11,2
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Fewer than 250 employees	15,9
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	250 or more employees	12,3
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets	Total 2021	15,6
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Fewer than 250 employees	17
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	250 or more employees	11,5
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and sales channels	Total 2021	16,5
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Fewer than 250 employees	16,3
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	250 or more employees	13,9
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception	Total 2021	16,1
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Fewer than 250 employees	40,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	250 or more employees	32,8
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements	Total 2021	40
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Fewer than 250 employees	54,9
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	250 or more employees	43,4
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost	Total 2021	53,9
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Fewer than 250 employees	21,7
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	250 or more employees	18,8
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting	Total 2021	21,5
% Companies with income of an international origin related to biotechnological activities	Fewer than 250 employees	22,8
% Companies with income of an international origin related to biotechnological activities	250 or more employees	16,4
% Companies with income of an international origin related to biotechnological activities	Total 2021	22,2
% Turnover representing income of an international origin related to biotechnological activities	Fewer than 250 employees	9,1
% Turnover representing income of an international origin related to biotechnological activities	250 or more employees	0,8
% Turnover representing income of an international origin related to biotechnological activities	Total 2021	1,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Fewer than 250 employees	57,9
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	250 or more employees	78
% Income of an international origin related to biotechnological activities distributed in: Income received from the EU	Total 2021	65,5
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Fewer than 250 employees	42,1
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	250 or more employees	22
% Income of an international origin related to biotechnological activities distributed in: Income received from other countries	Total 2021	34,5
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Fewer than 250 employees	93,7
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	250 or more employees	74,2
% Income of an international origin related to biotechnological activities by classification: Internacional trade in products and services	Total 2021	86,3
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Fewer than 250 employees	5,2
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	250 or more employees	23,6
% Income of an international origin related to biotechnological activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain	Total 2021	12,2
% Income of an international origin related with activities according to the classification: Operating source abroad	Fewer than 250 employees	0,5
% Income of an international origin related with activities according to the classification: Operating source abroad	250 or more employees	2,1
% Income of an international origin related with activities according to the classification: Operating source abroad	Total 2021	1,1
% Income of an international origin related with activities according to the classification: Other	Fewer than 250 employees	0,6
% Income of an international origin related with activities according to the classification: Other	250 or more employees	0
% Income of an international origin related with activities according to the classification: Other	Total 2021	0,4